Header Logo
Last Name

Michael J Mitchell MD

TitleAssociate Professor
InstitutionUniversity of Massachusetts Medical School
AddressUMass Memorial Health Care Inc.
365 Plantation Street, Biotech One
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DivisionAcademic Pathology

    Collapse Biography 
    Collapse education and training
    Boston College, Chestnut Hill, MA, United StatesBSChemistry
    Yale University School of Medicine, New Haven, CT, United StatesMD

    Collapse Overview 
    Collapse overview

    Academic Background

      Present Position:
      Director, Microbiology Services
      Department of Hospital Laboratories
      89 Puritan Road
      Waban, MA 02468
      Medical School:
      Yale University School of Medicine, MD (1978)

    Graduate Medical Education:

      1978-1981 Resident in Pediatrics, Yale-New Haven Hospital
      1981-1984 Fellow, Pediatric Infectious Diseases, Johns Hopkins Hospital
      1984-1987 Fellow, Microbiology Service, National Institutes of Health
      1990-1992 Fellow, Combined Program in Human Genetics, Harvard Medical School


      National Board of Medical Examiners (#201579), 1980.
      American Academy of Pediatrics, (#29383), 1983.
      American Board of Pathology, Medical Microbiology, 1986.
      American Board of Medical Genetics, Clinical Cytogenetics, 1993


      The Board of Medical Examiners of the State of Maryland, D33781 (expired 1987).
      Commonwealth of Massachusetts Board of Registration in Medicine, (Reg.#: 58562, Expires 6/18/03).

    Current Academic Appointment(s):

      Assistant Professor, Department of Pathology, University of Massachusetts School of Medicine

    Current Medical Staff Appointment(s):

      Staff Physician, UMass Memorial Group Practice


    I oversee laboratory and clinical aspects of the microbiology laboratories, including aerobicmichael Mitchell andanaerobicbacteriology, mycobacteriology, mycology, parasitology, and virology. I am involved with teachingandtraining of Medical Students, Pathology Residents, and Infectious Diseases Fellows (Department of Medicine). I am a member of the Steering Committee in the Department of Hospital Labs. I sit on the UMMMC Clinical Process Improvement Committee, and chair its Laboratory Advisory subcommittee. I also sit on the UMMMC Pharmacy and Therapeutics Antimicrobial Subcommittee, the UMMMC Infection Control Committee, and theUMMMC Disaster Committee.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Shepherd SJ, Issadore D, Mitchell MJ. Microfluidic formulation of nanoparticles for biomedical applications. Biomaterials. 2021 Apr 26; 274:120826. PMID: 33965797.
      View in: PubMed
    2. Yeom J, Guimaraes PPG, Ahn HM, Jung BK, Hu Q, McHugh K, Mitchell MJ, Yun CO, Langer R, Jaklenec A. Chiral Supraparticles for Controllable Nanomedicine. Adv Mater. 2019 Nov 05; e1903878. PMID: 31686433.
      View in: PubMed
    3. Bisso PW, Gaglione S, Guimarães PPG, Mitchell MJ, Langer R. Nanomaterial Interactions with Human Neutrophils. ACS Biomater Sci Eng. 2018 Dec 10; 4(12):4255-4265. PMID: 31497639.
      View in: PubMed
    4. Guimaraes PPG, Tan M, Tammela T, Wu K, Chung A, Oberli M, Wang K, Spektor R, Riley RS, Viana CTR, Jacks T, Langer R, Mitchell MJ. Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. J Control Release. 2018 Oct 02. PMID: 30290244.
      View in: PubMed
    5. Fenton OS, Olafson KN, Pillai PS, Mitchell MJ, Langer R. Advances in Biomaterials for Drug Delivery. Adv Mater. 2018 May 07; e1705328. PMID: 29736981.
      View in: PubMed
    6. Guimarães PPG, Gaglione S, Sewastianik T, Carrasco RD, Langer R, Mitchell MJ. Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. ACS Nano. 2018 Feb 27; 12(2):912-931. PMID: 29378114.
      View in: PubMed
    7. Nasajpour A, Mandla S, Shree S, Mostafavi E, Sharifi R, Khalilpour A, Saghazadeh S, Hassan S, Mitchell MJ, Leijten J, Hou X, Moshaverinia A, Annabi N, Adelung R, Mishra YK, Shin SR, Tamayol A, Khademhosseini A. Nanostructured Fibrous Membranes with Rose Spike-Like Architecture. Nano Lett. 2017 Oct 11; 17(10):6235-6240. PMID: 28819978.
      View in: PubMed
    8. Mitchell MJ, Webster J, Chung A, Guimarães PP, Khan OF, Langer R. Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun. 2017 Mar 20; 8:14179. PMID: 28317839.
      View in: PubMed
    9. Wayne EC, Chandrasekaran S, Mitchell MJ, Chan MF, Lee RE, Schaffer CB, King MR. TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer. J Control Release. 2016 Feb 10; 223:215-23. PMID: 26732555.
      View in: PubMed
    10. Mitchell MJ, Denais C, Chan MF, Wang Z, Lammerding J, King MR. Lamin A/C deficiency reduces circulating tumor cell resistance to fluid shear stress. Am J Physiol Cell Physiol. 2015 Dec 1; 309(11):C736-46. PMID: 26447202.
      View in: PubMed
    11. Mitchell MJ, Castellanos CA, King MR. Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow. Biomaterials. 2015 Jul; 56:179-86. PMID: 25934290.
      View in: PubMed
    12. Mitchell MJ, Castellanos CA, King MR. Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies. J Biomed Mater Res A. 2015 Oct; 103(10):3407-18. PMID: 25761664.
      View in: PubMed
    13. Kohn JC, Zhou DW, Bordeleau F, Zhou AL, Mason BN, Mitchell MJ, King MR, Reinhart-King CA. Cooperative effects of matrix stiffness and fluid shear stress on endothelial cell behavior. Biophys J. 2015 Feb 3; 108(3):471-8. PMID: 25650915.
      View in: PubMed
    14. Mitchell MJ, King MR. Leukocytes as carriers for targeted cancer drug delivery. Expert Opin Drug Deliv. 2015 Mar; 12(3):375-92. PMID: 25270379.
      View in: PubMed
    15. Bajpai S, Mitchell MJ, King MR, Reinhart-King CA. A microfluidic device to select for cells based on chemotactic phenotype. Technology (Singap World Sci). 2014 Jun; 2(2):101-105. PMID: 24999488.
      View in: PubMed
    16. Mitchell MJ, Lin KS, King MR. Fluid shear stress increases neutrophil activation via platelet-activating factor. Biophys J. 2014 May 20; 106(10):2243-53. PMID: 24853753.
      View in: PubMed
    17. Mitchell MJ, King MR. Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering. Expert Rev Anticancer Ther. 2014 Jun; 14(6):641-4. PMID: 24791860.
      View in: PubMed
    18. Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):930-5. PMID: 24395803.
      View in: PubMed
    19. Mitchell MJ, King MR. Physical biology in cancer. 3. The role of cell glycocalyx in vascular transport of circulating tumor cells. Am J Physiol Cell Physiol. 2014 Jan 15; 306(2):C89-97. PMID: 24133067.
      View in: PubMed
    20. Cao TM, Mitchell MJ, Liesveld J, King MR. Stem cell enrichment with selectin receptors: mimicking the pH environment of trauma. Sensors (Basel). 2013 Sep 17; 13(9):12516-26. PMID: 24048341.
      View in: PubMed
    21. Mitchell MJ, King MR. Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013; 3:44. PMID: 23467856.
      View in: PubMed
    22. Mitchell MJ, King MR. Fluid Shear Stress Sensitizes Cancer Cells to Receptor-Mediated Apoptosis via Trimeric Death Receptors. New J Phys. 2013 Jan 18; 15:015008. PMID: 25110459.
      View in: PubMed
    23. Mitchell MJ, King MR. Shear-induced resistance to neutrophil activation via the formyl peptide receptor. Biophys J. 2012 Apr 18; 102(8):1804-14. PMID: 22768936.
      View in: PubMed
    24. Mitchell MJ, Chen CS, Ponmudi V, Hughes AD, King MR. E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. J Control Release. 2012 Jun 28; 160(3):609-17. PMID: 22421423.
      View in: PubMed
    25. Mitchell MJ, Castellanos CA, King MR. Nanostructured Surfaces to Target and Kill Circulating Tumor Cells While Repelling Leukocytes. J Nanomater. 2012; 2012. PMID: 25152752.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Mitchell's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description